EYPT Stock Crashes On Duravyu Data But Catalysts Loom

EyePoint Inc. stocks have been trading up by 10.37 percent following highly positive sentiment around its latest therapeutic developments.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading EYPT

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Phase 3 LUGANO data for DURAVYU missed the primary vision endpoint on the full dataset, but an ad hoc analysis excluding a small asymmetric cohort showed non‑inferiority versus aflibercept.
Secondary LUGANO outcomes were strong, with a 42% reduction in treatment burden, high supplement‑free rates, and a clean safety profile that supports ongoing development.
The LUCIA Phase 3 trial in wet AMD is fully enrolled, with topline data expected in Q4 2026 and a potential DURAVYU NDA in 2027 alongside DME Phase 3 readouts.
Analysts trimmed price targets on EyePoint Pharmaceuticals but mostly kept Buy or Overweight views; JPMorgan cut to Neutral after EYPT plunged about 69% to $4.57.
Q2 brought a wider EPS loss of ($1.09) versus ($0.96) expected, but revenue of $507,000 topped estimates, leaving EYPT trading driven mainly by clinical catalysts.

Live Update At 12:32:23 EDT: On Tuesday, August 18, 2026 EyePoint Inc. stock [NASDAQ: EYPT] is trending up by 10.37%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

EYPT is trading like a classic event‑driven biotech — violent swings wrapped around clinical headlines. The daily chart shows EYPT collapsing from $14.75 on 2026/08/14 to $4.87 on 2026/08/17, then bouncing to $5.38 on 2026/08/18. That’s a brutal drawdown followed by a dead‑cat style snapback, exactly the kind of volatility short‑term traders hunt.

Intraday, the 5‑minute tape on EYPT tells the same story. After a gap from $4.73 at the open to above $5.30, the stock spent the morning grinding between roughly $5.20 and $5.40. That tight intraday range after a huge prior‑day washout signals active but more balanced two‑sided trading — shorts locking in profits while dip buyers probe for a floor.

More Breaking News

On the fundamentals, EYPT is still deep in development mode. Q2 revenue was just $507,000 against annual revenue of about $31.4M, with a profit margin near ‑11,000% and negative cash flow. Yet EyePoint Pharmaceuticals holds $110.6M in cash and a strong current ratio of 4.5, giving it runway to push DURAVYU toward those 2027 milestones. For traders, the message is simple: the balance sheet buys time, but the chart will live and die on data headlines.

Why Traders Are Watching EYPT’s Volatility

EYPT went from a slow‑burn catalyst setup to a full‑blown biotech wreck in a matter of days. The trigger was the Phase 3 LUGANO topline readout for DURAVYU in wet age‑related macular degeneration, which failed its primary BCVA non‑inferiority endpoint on the full dataset. The market doesn’t read footnotes first — it sees “primary endpoint miss” and hits the sell button. That’s how you get a 69% crash to $4.57.

But when traders dig into the EYPT details, the picture gets more nuanced. EyePoint Pharmaceuticals said a small 4% asymmetric cohort with vision loss — deemed unrelated to wet AMD — dragged the primary analysis. Excluding that group, DURAVYU matched on‑label aflibercept in vision outcomes while delivering a 42% reduction in treatment burden, durable six‑month dosing, high supplement‑free rates, and favorable safety.

That combo explains the split reaction on Wall Street. Jefferies slashed its EYPT price target from $30 to $8 but kept a Buy rating, flagging LUCIA as a potential “clean win” in roughly eight weeks. Laidlaw also trimmed its EYPT target slightly, to $48 from $50, yet argued the LUGANO miss looked like a one‑off driven by trial imbalance, not a broken drug.

At the same time, JPMorgan downgraded EyePoint Pharmaceuticals to Neutral as the stock imploded, showing how shaken confidence has become. Yet consensus still leans bullish, with an average target far above current levels. For active traders, that gap between smashed price and still‑optimistic models sets up a classic battleground: either EYPT proves the skeptics right with more bad data, or any clean DURAVYU reading fuels a vicious short squeeze.

Conclusion

EYPT is now a textbook high‑beta biotech trade. Q2 numbers underline the reality: revenue at $507,000 and an EPS loss of ($1.09) show EyePoint Pharmaceuticals is spending heavily, with negative returns on equity and assets and free cash flow around ‑$63.5M. The value for traders is all about what DURAVYU becomes, not what the current income statement looks like.

The roadmap is clear. EYPT has LUCIA, an identically designed Phase 3 trial in wet AMD, fully enrolled with topline data targeted for Q4 2026. EyePoint Pharmaceuticals also points to a potential DURAVYU NDA in the first half of 2027 and separate Phase 3 DME trials set for 2027 readouts. That gives a defined catalyst ladder — and plenty of room for sharp rallies and selloffs in between. For short‑term and swing traders, that kind of catalyst‑rich runway demands serious planning before each trading day. As Tim Bohen, lead trainer with StocksToTrade says, “Preparation is half the trade. By the time the bell rings, my decisions are nearly made.” In a name like EYPT, where binary news can move the stock dramatically, that style of preparation‑driven trading can be the difference between surviving the volatility and getting caught in it.

Analyst moves mirror that tension. Jefferies, Laidlaw, H.C. Wainwright, and others cut targets but kept Buy or Overweight on EYPT, while JPMorgan stepped back to Neutral after the crash. As Tim Sykes likes to remind traders, “The market doesn’t care about your opinion — it cares about catalysts and price action. Study both, cut losses fast, and never fall in love with a story.” For anyone eyeing EYPT, that mindset is not optional — it’s survival.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!